ImmunityBio and Alkermes presented positive data of their compounds at ASCO

CLINICAL AND REGULATORY

Alkermes presented positive ARTISTRY-1 data at 2022 ASCO

Alkermes presented at ASCO data from the ARTISTRY-1 clinical trial for nemvaleukin alfa, the company's investigational, engineered IL-2 variant immunotherapy. The presentations included efficacy and safety data from ARTISTRY-1, a phase 1/2 study evaluating the safety, tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with Keytruda. Nemvaleukin demonstrated anti-tumor activity with durable responses as monotherapy in CPI-experienced melanoma and RCC patients. In the combination study, among the 137 total evaluable patients, four CRs and 18 PRs were observed, SD was observed in 60 patients, and overall median DOR was 23 weeks.

ImmunityBio announces results for bladder cancer and pancreatic cancer at ASCO

The results, which were presented during the 2022 ASCO, demonstrated the strong and diverse growth of ImmunityBio’s immunotherapy platform that includes an IL-15 superagonist (N-803), adenovirus vaccine platform, and engineered off-the-shelf NK cell therapy. The data demonstrate a potential new option for BCG-unresponsive non-muscle invasive bladder cancer patients who were treated with Bacillus Calmette-Guérin (BCG) plus N-803 (Anktiva) and the doubling of historic OS rates in patients with advanced pancreatic cancer who were treated with the Nant Cancer Vaccine, N-803 (Anktiva, IL-15 cytokine fusion protein), and off-the-shelf PDL1-targeted high-affinity NK cell (PDL1 t-haNK) infusion.